Profile
Aulis Capital is a venture capital firm with a focus on life sciences and healthcare, based across Hong Kong, Beijing, Shanghai, Silicon Valley, and Boston. The firm was founded in October 2025 by Nisa Leung, a former managing partner at Qiming Venture Partners, and is led by a team of experienced operators, investors, and advisors. Aulis Capital distinguishes itself by leveraging its extensive global network and expertise in the medical technology field to support transformative healthcare innovations.
The firm invests in early- and growth-stage companies that are developing innovative drugs, digital healthcare solutions, and AI-driven healthcare technologies. Aulis Capital typically invests in the $10-50 million range for Series A through late-stage companies. The firm recently closed its first fund, Aulis Capital Fund I, with $200 million in commitments. It focuses geographically on nurturing startups in key regions around the globe.
Notable investments by Aulis Capital include EpiBiologics, a US-based company that raised $107 million in a Series B round to advance its protein degradation pipeline. The firm is committed to fostering companies that redefine potential in the medical sector.
Industry
Aulis Capital Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Aulis Capital Fund I, L.P.
|
Venture Capital (VC)
|
Digital
Healthcare Services
AI
Life Sciences
|
Seed
Late Stage (Series C+)
|
North America
Asia
|
$10-50 m
|
$200 M
|
November 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.